Regeneron Pharmaceuticals (REGN) Accounts Payables (2009 - 2026)

Regeneron Pharmaceuticals has reported Accounts Payables for 18 years, with the latest figure at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 45.58% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (up 45.58% YoY), and the FY2025 full-year result was $939.0 million, up 18.94% from the prior year.
• Accounts Payables for Q1 2026 stood at $1.0 billion, up from $939.0 million in the prior quarter.
• The five-year high for Accounts Payables was $1.0 billion in Q1 2026, with the low at $470.3 million in Q1 2022.
• Average Accounts Payables over 5 years is $661.1 million, with a median of $599.5 million recorded in 2023.
• Year-over-year, Accounts Payables slipped 13.37% in 2022 and jumped 81.74% in 2025.
• Tracing REGN's Accounts Payables over 5 years: stood at $589.2 million in 2022, then grew by 2.95% to $606.6 million in 2023, then surged by 30.15% to $789.5 million in 2024, then grew by 18.94% to $939.0 million in 2025, then gained by 9.38% to $1.0 billion in 2026.
• The last three Accounts Payables figures came in at $1.0 billion (Q1 2026), $939.0 million (Q4 2025), and $903.8 million (Q3 2025), per Business Quant data.

Peer Comparison